Acumen Pharmaceuticals (NASDAQ:ABOS – Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.14), Zacks reports. During the same quarter in the previous year, the firm posted ($0.24) EPS.
Acumen Pharmaceuticals Trading Up 1.2 %
ABOS stock traded up $0.03 during trading on Thursday, hitting $2.56. 56,804 shares of the company traded hands, compared to its average volume of 326,075. The company has a debt-to-equity ratio of 0.12, a quick ratio of 17.37 and a current ratio of 17.37. The company has a 50-day moving average of $2.61 and a 200-day moving average of $2.80. The firm has a market capitalization of $153.80 million, a PE ratio of -1.83 and a beta of 0.04. Acumen Pharmaceuticals has a 1 year low of $2.08 and a 1 year high of $5.09.
Analysts Set New Price Targets
A number of research firms have weighed in on ABOS. Citigroup upgraded Acumen Pharmaceuticals to a “strong-buy” rating in a research report on Friday, July 26th. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of Acumen Pharmaceuticals in a research note on Wednesday. Finally, UBS Group decreased their price target on shares of Acumen Pharmaceuticals from $14.00 to $6.00 and set a “buy” rating on the stock in a research note on Thursday, August 15th.
Acumen Pharmaceuticals Company Profile
Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.
Featured Stories
- Five stocks we like better than Acumen Pharmaceuticals
- Do ETFs Pay Dividends? What You Need to Know
- 3 GARP Stocks Offering Strong Growth: Aptiv, Allstate, Barrick
- Breakout Stocks: What They Are and How to Identify Them
- Mouse Rising: The Iger Investment Pays Off for Disney Investors
- How to Calculate Stock Profit
- Can CAVA Stock Be the Next Chipotle? Earnings Can Help
Receive News & Ratings for Acumen Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acumen Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.